Pemetrexed Plus Platinum As First-line Treatment For Advanced Lung Adenocarcinoma

Objective:To observe the clinical efficacy and toxicity of pemetrexed plus platinum (PPC) as the first-line treatment for advanced lung adenocarcinoma.Methods:This retrospective study enrolled17patients with chemotherapy-naive advanced (IIIB/IV) lung adenocarcinoma treated at The First Affiliated Hospital of College of Medicine, Zhejiang University from July2011to December2013. All patients received pemetrexed plus platinum as first-line treatment. The primary endpoints were objective response rate, disease control rate, progression-free survival and toxicity.Results:The objective response rate (ORR) was41.2%(7/17). The disease control rate (DCR) was88.2%(15/17). The median progression-free survival (mPFS) was3.27months. Fisher’s exact test showed that chemotherapy regimens, PS score, gender, age, smoking status, and neoplasm staging were no statistically difference in efficacy. Univariate analysis showed that smoking status was significantly correlated with PFS. Rate of Grade Ⅲ-Ⅳ adverse events was low. The main toxicities were gastrointestinal reaction (10/17) and leucopenia (6/17).Conclusion:The efficacy of pemetrexed plus platinum as the first-line treatment of patients with advanced lung adenocarcinoma was exact, and patients can tolerate. The smoking status may be correlated with PFS.